1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Legislation

US FDA's Consumer Health Oversight Absent From Appropriators’ Request For COVID-19 Assessment

At 90 And Counting, Will Supplement Warnings Merit Mention In Response?

 
• By Malcolm Spicer

House appropriators don’t mention the consumer health market in requesting a report on FDA’s response to COVID-19, but the agency’s frequent warnings about products marketed with unlawful claims could merit mentioning. Encouraging accelerated production of hand sanitizers while also ensuring the additional supplies are safe is another component of its COVID-19 response that could be covered in an assessment of its response to the pandemic.

Test result of a Corona test. Hand turns a dice and changes the expression "positive COVID19" to "negative COVID19".

US House appropriators don’t mention the consumer health market in requesting a report on the Food and Drug Administration’s response to the COVID-19 pandemic, but the agency’s frequent warnings about products marketed with unlawful claims could merit mentioning in its report.

Encouraging accelerated product of hand sanitizers while also ensuring the additional supplies are safe is another component of its COVID-19 response that the Appropriation Committee didn’t mention but

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

US Tariffs Pose ‘Existential Threat’ To EU Medical Devices Industry

 
• By David Ridley

AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By David Ridley

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.